Literature DB >> 1323476

Effects of subunit types of the recombinant GABAA receptor on the response to a neurosteroid.

S H Zaman1, R Shingai, R J Harvey, M G Darlison, E A Barnard.   

Abstract

When vertebrate brain poly(A)+ RNA is expressed in Xenopus oocytes the response of the GABA receptors formed is found to be inhibited allosterically by a neurosteroid, pregnenolone sulphate (PS). This negative modulation was reproduced after expressing RNAs encoding bovine GABAA receptor subunits in the combinations alpha i + beta 1, or alpha i + beta 1 + gamma 2 (where i = 1, 2 or 3). The characteristics of this inhibition vary significantly with the type of the alpha subunit (alpha 1, alpha 2, or alpha 3) used. When the bovine gamma 2L alternate form of the gamma 2 subunit was replaced by the human gamma 2S subunit, the behaviour was unchanged: the human gamma 2S subunit used is a newly-cloned form, which encodes a polypeptide with two amino acid differences from the human gamma 2 subunit previously described. The results of co-application of PS and 3 alpha-hydroxy-5 alpha-pregnan-ol-20-one, a neurosteroid which is a positive modulator of the GABAA receptor, indicate that these act at different sites on the receptor. PS also increases the desensitisation of the receptor by GABA. This effect, also, is alpha-subunit-type dependent and occurs by an acceleration of the fast phase of desensitisation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323476     DOI: 10.1016/0922-4106(92)90106-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  Neurosteroid modulation of GABA IPSCs is phosphorylation dependent.

Authors:  A Fáncsik; D M Linn; J G Tasker
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

2.  Inhibition of the GABAA Receptor by Sulfated Neurosteroids: A Mechanistic Comparison Study between Pregnenolone Sulfate and Dehydroepiandrosterone Sulfate.

Authors:  Divya Sachidanandan; Amal Kanti Bera
Journal:  J Mol Neurosci       Date:  2015-03-01       Impact factor: 3.444

3.  Pregnenolone sulfate block of GABA(A) receptors: mechanism and involvement of a residue in the M2 region of the alpha subunit.

Authors:  G Akk; J Bracamontes; J H Steinbach
Journal:  J Physiol       Date:  2001-05-01       Impact factor: 5.182

Review 4.  Neurosteroid modulation of native and recombinant GABAA receptors.

Authors:  J J Lambert; D Belelli; C Hill-Venning; H Callachan; J A Peters
Journal:  Cell Mol Neurobiol       Date:  1996-04       Impact factor: 5.046

5.  Bidirectional effects of the neuroactive steroid tetrahydrodeoxycorticosterone on GABA-activated Cl- currents in cultured rat hypothalamic neurons.

Authors:  C H Wetzel; H Vedder; F Holsboer; W Zieglgänsberger; R A Deisz
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 6.  The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes.

Authors:  W Hevers; H Lüddens
Journal:  Mol Neurobiol       Date:  1998-08       Impact factor: 5.590

7.  Activation-dependent properties of pregnenolone sulfate inhibition of GABAA receptor-mediated current.

Authors:  Lawrence N Eisenman; Yejun He; Christopher Fields; Charles F Zorumski; Steven Mennerick
Journal:  J Physiol       Date:  2003-08-01       Impact factor: 5.182

8.  Neuroactive steroids have multiple actions to potentiate GABAA receptors.

Authors:  Gustav Akk; John R Bracamontes; Douglas F Covey; Alex Evers; Tim Dao; Joe Henry Steinbach
Journal:  J Physiol       Date:  2004-05-14       Impact factor: 5.182

9.  Residues in the first transmembrane domain of the Caenorhabditis elegans GABA(A) receptor confer sensitivity to the neurosteroid pregnenolone sulfate.

Authors:  Bryan Wardell; Purba S Marik; David Piper; Tina Rutar; Erik M Jorgensen; Bruce A Bamber
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 10.  Neurosteroid regulation of central nervous system development.

Authors:  Synthia H Mellon
Journal:  Pharmacol Ther       Date:  2007-06-16       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.